WuXi Biologics (Cayman) Inc. Share Price
Equities
2269
KYG970081173
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.32 HKD | +0.92% |
|
-1.75% | +25.06% |
| 09:35am | Morgan Stanley's long position in Wuxi Biologics (Cayman) decreases to 2.11% on Jan 20 from 5.58%, HKEX shows | RE |
| 01-16 | WuXi Biologics Shareholder to Sell Shares | MT |
| Capitalization | 145B 163B 20.84B 17.74B 16.48B 15.45B 28.77B 1,909B 30.5B 188B 74.54B 902B 78.17B 76.56B 3,300B | P/E ratio 2025 * |
32.5x | P/E ratio 2026 * | 28.6x |
|---|---|---|---|---|---|
| Enterprise value | 139B 155B 19.88B 16.92B 15.71B 14.73B 27.43B 1,821B 29.08B 179B 71.08B 860B 74.53B 73.01B 3,147B | EV / Sales 2025 * |
6.43x | EV / Sales 2026 * | 5.47x |
| Free-Float |
86.37% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | +0.92% | ||
| 1 week | -1.75% | ||
| Current month | +25.06% | ||
| 1 month | +18.65% | ||
| 3 months | +9.77% | ||
| 6 months | +40.43% | ||
| Current year | +25.06% |
| 1 week | 36.68 |  | 39.7 |
| 1 month | 31.1 | | 40.4 |
| Current year | 31.1 | | 40.4 |
| 1 year | 16.2 | | 42.6 |
| 3 years | 10.14 | | 72.5 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 54 | 31/12/2015 |
Ming Tu
DFI | Director of Finance/CFO | 56 | 22/08/2021 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 55 | 30/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 58 | 31/01/2014 |
Zhi Sheng Chen
BRD | Director/Board Member | 54 | 31/01/2014 |
Yan Ling Cao
BRD | Director/Board Member | 42 | 30/04/2016 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.27% | 2.99% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.92% | -1.75% | +122.90% | -44.89% | 20.65B | |
| +1.09% | +1.82% | +14.16% | +94.55% | 50.26B | |
| 0.00% | -5.76% | +78.85% | +0.10% | 41.75B | |
| -2.55% | -2.43% | +102.34% | +639.09% | 34.21B | |
| -0.41% | +8.95% | -2.75% | -17.37% | 29.73B | |
| +0.40% | -2.75% | +40.54% | -21.90% | 20.51B | |
| +3.65% | -4.43% | +86.10% | +143.72% | 13.28B | |
| +0.78% | +2.73% | -28.99% | +292.49% | 13.39B | |
| +3.07% | -8.67% | +169.00% | - | 12.46B | |
| +0.97% | +2.49% | +32.01% | +164.72% | 11.98B | |
| Average | +0.78% | -1.74% | +61.42% | +138.94% | 24.82B | |
| Weighted average by Cap. | +0.35% | -0.69% | +56.55% | +137.95% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 21.54B 24.09B 3.09B 2.63B 2.44B 2.29B 4.26B 283B 4.52B 27.88B 11.05B 134B 11.58B 11.35B 489B | 25.05B 28.02B 3.59B 3.06B 2.84B 2.66B 4.96B 329B 5.26B 32.43B 12.85B 155B 13.47B 13.2B 569B |
| Net income | 4.46B 4.99B 640M 545M 506M 474M 884M 58.64B 937M 5.78B 2.29B 27.7B 2.4B 2.35B 101B | 5.07B 5.67B 727M 619M 575M 539M 1B 66.63B 1.06B 6.56B 2.6B 31.47B 2.73B 2.67B 115B |
| Net Debt | -6.75B -7.55B -968M -824M -766M -718M -1.34B -88.7B -1.42B -8.74B -3.46B -41.9B -3.63B -3.56B -153B | -8.27B -9.25B -1.19B -1.01B -938M -879M -1.64B -109B -1.74B -10.71B -4.24B -51.34B -4.45B -4.36B -188B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 39.32 $ | +0.92% | 22,101,031 |
| 22/01/26 | 38.96 $ | +1.46% | 35,375,250 |
| 21/01/26 | 38.40 $ | +3.50% | 29,655,920 |
| 20/01/26 | 37.10 $ | -2.01% | 28,301,690 |
| 19/01/26 | 37.86 $ | -4.83% | 41,306,910 |
Delayed Quote Hong Kong S.E., January 23, 2026 at 08:08 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition